Zobrazeno 1 - 10
of 136
pro vyhledávání: '"Relapsed Small Cell Lung Cancer"'
Publikováno v:
Case Reports in Oncology, Vol 14, Iss 3, Pp 1652-1659 (2021)
Case Reports in Oncology
Case Reports in Oncology
Tumor lysis syndrome (TLS) is an oncologic emergency most frequently associated with initial treatment of hematologic malignancies and high-tumor burden solid tumors such as small-cell lung cancer (SCLC). Most often, TLS is associated with cytotoxic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd1f64a01d017ca5935cf198f94f384f
https://doi.org/10.1159/000519566
https://doi.org/10.1159/000519566
Autor:
Uldis Vikmanis, Viktors Kozirovskis, Elīna Zandberga, Gunta Purkalne, Melita Magone, Aija Linē
Publikováno v:
Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.. 75:335-342
Cancer stem cells may be responsible for tumour regrowth and acquisition of resistance in small cell lung cancer (SCLC). The Hedgehog pathway regulates survival and proliferation of tissue progenitor and stem cell populations, promoting the expressio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::538abe63aa2930b801e8cbbb59700830
https://doi.org/10.2478/prolas-2021-0049
https://doi.org/10.2478/prolas-2021-0049
Publikováno v:
Advances in Therapy
Introduction The survival of patients with relapsed small cell lung cancer (SCLC) has achieved little progress in the last several decades. ALTER1202 confirmed the efficacy and safety of anlotinib as a third- or further-line option for relapsed SCLC.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45cc2dfcee3dde5f5d771852da27e4ca
https://doi.org/10.1007/s12325-021-01889-2
https://doi.org/10.1007/s12325-021-01889-2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Jose María Mazarico, Vicente Alfaro, Luis Paz-Ares, Elizabeth Jimenez-Aguilar, Javier Baena, Ali Zeaiter, Carmen Kahatt, Andrea Modrego
Publikováno v:
Future Oncology. 17:2279-2289
Lurbinectedin is a marine-derived drug that inhibits transcription, a process that is frequently dysregulated in small cell lung cancer. The activity of lurbinectedin has been studied in many solid tumors, showing not only promising results but also
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cad8907877698650856fe422556a3a4d
https://doi.org/10.2217/fon-2020-1212
https://doi.org/10.2217/fon-2020-1212
Autor:
Isamu Okamoto, Yuichi Takiguchi, Nobuyuki Yamamoto, Ichiro Yoshino, Takehito Shukuya, Etsuo Miyaoka, Koichi Takayama, Kazuhisa Takahashi, Yasushi Shintani, Meinoshin Okumura, Katsuhiko Naoki, Satoshi Igawa, Ikuo Sekine, Katsuyuki Kiura, Akira Inoue
Publikováno v:
Lung Cancer. 146:160-164
Objectives Most patients with small-cell lung cancer (SCLC) experience relapse because of the emergence of drug-resistant tumor cells. Therefore, second-line therapy is subsequently required to prolong their survival. However, it is unclear whether s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcdf70bb5f0ea617de0651f6b295b4e0
https://doi.org/10.1016/j.lungcan.2020.05.038
https://doi.org/10.1016/j.lungcan.2020.05.038
Autor:
Jie Zhang, Guangming Tian, Xiangjuan Ma, Di Wu, Sen Han, Ling Dai, Ziran Zhang, Yang Wang, Weiheng Hu, Jian Fang, Jun Nie, Jindi Han, Jieran Long, Xiaoling Chen
Publikováno v:
International Journal of Cancer
The purpose of this prospective phase II clinical trial was to investigate the efficacy and safety of anlotinib in patients with relapsed small cell lung cancer (SCLC). Forty‐five patients with relapsed SCLC were enrolled and treated with anlotinib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91f46162c910382460f93bfa16ec7bf5
http://europepmc.org/articles/PMC7689882
http://europepmc.org/articles/PMC7689882
Autor:
Kazushige Wakuda
Publikováno v:
Transl Lung Cancer Res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c26fd18fb79bb51b786d7d6f52e887a
https://doi.org/10.21037/tlcr.2020.03.10
https://doi.org/10.21037/tlcr.2020.03.10
Autor:
Deyan Davidov
Publikováno v:
Journal of IMAB, Vol 16, Iss 3, Pp 70-73 (2010)
Objectives: Single agent intravenous Topotecan is an effective treatment for small cell lung cancer /SCLC/ after failure of first- line chemotherapy. The aim of this study was to evaluate the efficacy and toxicity of intravenous Topotecan in recurren
Externí odkaz:
https://doaj.org/article/92e49ad2bcb04b88bffea317d692c2d0
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.